N30 Pharma, Inc.: Series B $10M

Posted in I - Series B, Q - 2Q10, R - ROCKY MOUNTAIN, X - Asthma, X - COPD, X - IBD, XX - CO

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

Feb

2010

Flexion Therapeutics, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Autoimmune, X - IBD, X - Tinnitus, XX - MA

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

May

2009

Lycera Corp.: Series A $36M

Posted in I - Series A, Q - 2Q09, R - MID WEST, X - IBD, X - Lupus, X - RA, X - Therapeutic Platform, XX - MI

Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.

Apr

2007

ChemoCentryx, Inc.: Series D $29.9M

Posted in I - Series D, R - WEST, X - IBD, X - Inflammation, X - Oncology

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

to top of page...